Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials.

doi:10.1038/s41591-025-03638-2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials.

Nature medicine - 1 Jun 2025

Zhao Shen, Cheng Ying, Wang Qiming, Li Xingya, Liao Jun, Rodon Jordi, Meng Xiangjiao, Luo Yongzhong, Chen Zhendong, Wang Wei, Yi Tienan, Li Yongsheng, Yin Yongmei, Xu Huiting, Yu Guohua, Mi Yanjun, Fan Yun, Wainberg Zev A, Wang Xiang, Su Cuiyun, Yu Qitao, Lai Shuzhen, Sun Longhua, Zhuang Wu, Wang Xian, Yang Jiacheng, Li Yaling, Ge Junyou, Li Jin, Zhang Li, Fang Wenfeng

Abstract excerpt

Trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) is a promising anticancer agent that has shown remarkable efficacy in several malignancies. However, in lung cancer, two phase 3 trials on TROP2-ADCs in unselected patients with advanced non-small-cell lung cancer (NSCLC) have both failed. Sacituzumab tirumotecan (sac-TMT) is a novel TROP2-directed ADC. Here we report the efficacy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, Neoplasm

Share to Camptothecin

Share to Carcinoma, Non-Small-Cell Lung

Share to Cell Adhesion Molecules

Share to ErbB Receptors

Share to Immunoconjugates

Share to Progression-Free Survival

Source

Open in PubMed

Identifiers

PMID: 40210967
DOI: 10.1038/s41591-025-03638-2

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials.PMID 40210967Read ↗

Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Trop-2 expression in non–small cell lung cancerSemantic proximity Read ↗

The Utility of Tissue-Agnostic Drugs in Lung Cancer Treatment.Semantic proximity Read ↗

The emerging role of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer with acquired resistance to third-generation EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 Study.Semantic proximity Read ↗

Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.Semantic proximity Read ↗

Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study.Semantic proximity Read ↗

Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations.Semantic proximity Read ↗

Noninvasive molecular imaging using anti-Trop-2 aptamer for targeted therapy of small cell lung cancerSemantic proximity Read ↗

ADC Target Profiling in NSCLC: Generalizable AI Separates TROP-2 and cMET Phenotypes.Semantic proximity Read ↗

Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer.Semantic proximity Read ↗

Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.